Daniel Ontaneda, MD, PhD, an associate professor of neurology at the Cleveland Clinic Lerner College of Medicine, gave thoughts and perspectives on some of the emerging, promising advances in multiple sclerosis care expected to come to fruition in 2025.
The assistant professor in the department of neurology at Mount Sinai talked about a recent study that highlighted how socioeconomic status and diet could significantly impact physical and cognitive outcomes in patients with MS. [WATCH TIME: 2 minutes]
PAP therapy significantly improved cognitive function, particularly executive and psychomotor skills, in patients with Parkinson disease with comorbid obstructive sleep apnea.
Using more than 100,000 claims, the 36-month cumulative risk of acute myocardial infarction and stroke was similar between erenumab and other anti-CGRP mAbs, with minimal residual bias.
Treatment strategies varied across cases, incorporating therapies like prednisolone, rituximab, and azathioprine, with overall positive outcomes and symptom improvement.
Here's some of what is coming soon to NeurologyLive® this week.
Catch up on any of the neurology news headlines you may have missed over the course of February 2025, compiled all into one place by the NeurologyLive® team.
The instructor in the department of radiology at Weill Cornell Medicine discussed how structural and functional brain connectomes can potentially improve predictions of MS progression and treatment response. [WATCH TIME: 4 minutes]
Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is on Parkinson disease.
A post-hoc analysis of patients from the CHAMPION-NMOSD trial revealed that the majority received their initial meningococcal vaccination within 6-months of their last rituximab dose.
Lecanemab, a monoclonal antibody directed against aggregated soluble and insoluble forms of amyloid-ß, remains under review, with a decision expected in the coming months.
Neurology News Network. for the week ending March 8, 2025. [WATCH TIME: 3 minutes]
Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending March 7, 2025.
The professor of neurosurgery and physiology at University of Colorado School of Medicine talked about how vagus nerve stimulation may promote remyelination and functional recovery in multiple sclerosis. [WATCH TIME: 4 minutes]
BXCL501, an orally dissolving dexmedetomidine film, showed positive results in reducing agitation symptoms in patients with Alzheimer disease during the phase 3 TRANQUILITY trial.
The child neurologist and neuroimmunologist at Nationwide Children’s Hospital provided clinical insight on the complexities of treating pediatric MOGAD, including treatment options, decision-making factors, and emerging therapies. [WATCH TIME: 4 minutes]
Mind Moments®, a podcast from NeurologyLive®, brings you an exclusive interview with Sonal Bhatia, MD, FACNS. [LISTEN TIME: 24 minutes]
A late-breaking study presented at the 2025 ACTRIMS Forum reported that a modified Atkins diet reduced inflammation and altered immune cell metabolism in multiple sclerosis.
At the 2025 ACTRIMS Forum, the director of the MS Comprehensive Care Center at Stony Brook Medicine discussed the evolution of high-efficacy treatments for MS. [WATCH TIME: 4 minutes]
Based on the results of PROGRESS and the previous RELIEF-DPN-1 study, the 10 mg dose of pilavapadin was selected to move forward in clinical development for diabetic peripheral neuropathic pain.
The assistant professor in the neurology department at the University of Utah in Salt Lake City discussed advancing personalized medicine for patients with neuromyelitis optica spectrum disorder, a rare disorder of the central nervous system. [WATCH TIME: 4 minutes]
Data from more than 16,000 trial participants point to possible challenges with assessing and safely administering novel therapeutics among those with comorbidities—which may be present in as much as half of the patient population.
In the CAVS-MS study, 19% of participants with atypical or radiological-only presentations met the 2024 McDonald Criteria for MS, enabling earlier treatment initiation.
GFAP changes positively correlated with gadolinium-enhancing lesion volume (P = 0.18) and negatively with left ventricular volume (P = -0.19).
The vice president and senior global program lead for Hematology and Cell Therapy at BMS gave clinical commentary on encouraging phase 1 findings of CD19-XT in progressive and relapsing multiple sclerosis.
In both HERCULES and GEMINI trials, tolebrutinib reduced the risk of 6-month confirmed disability worsening, especially in participants with at least 4 baseline paramagnetic rim lesions.
With a scheduled PDUFA date of August 31, 2025, deramiocel looks to become the first marketed treatment for cardiomyopathy in DMD, one of the leading causes of death in this patient population.
Originally approved in 2007, eculizumab (Soliris; Alexion/AstraZeneca) is now available to treat both adult and pediatric patients with generalized myasthenia gravis, becoming the first available option for younger patients with the disease.
The pediatric neurologist at Children’s Hospital of Philadelphia gave perspective on some of the main issues the clinical community is figuring out with gene therapies and their integration to clinical practice. [WATCH TIME: 3 minutes]
Overall, treatment with the anti-tau monoclonal antibody resulted in no serious or severe adverse events, with additional results expected to be presented at an upcoming scientific conference.
